Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment‐naïve Chinese patients: Analysis of results from the CONSENT trial
Published Apr 1, 2018 · L. Ji, Jing Liu, Jing Yang
Diabetes
18
Citations
2
Influential Citations
Abstract
Metformin treatment for type 2 diabetes mellitus (T2DM) can be limited by gastrointestinal (GI) adverse events (AEs), resulting in treatment discontinuation. We investigated whether once‐daily metformin extended release (XR) is superior in terms of GI tolerability, with non‐inferior efficacy, compared with thrice‐daily metformin immediate release (IR) in treatment‐naïve Chinese patients with T2DM.
Study Snapshot
Key takeawayOnce-daily metformin extended release (XR) is superior in gastrointestinal tolerability compared to thrice-daily metformin immediate release (IR) for treating type 2 diabetes in treatment-naive Chinese patients.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.